Intervacc AB

Equities

IVACC

SE0009607252

Biotechnology & Medical Research

Delayed Nasdaq Stockholm 07:48:33 2024-03-28 am EDT 5-day change 1st Jan Change
3.7 SEK +0.95% Intraday chart for Intervacc AB +2.78% -41.55%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Intervacc AB Announces Changes in the Nomination Committee CI
Intervacc's Acting CEO Assumes Role Permanently MT
Jonas Sohlman Appoints as New CEO for Intervacc AB CI
Intervacc AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Intervacc AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Intervacc, Moredun Scientific Receive Eurostars Grant for Vaccine Against Pig Infection MT
Intervacc AB Awards Prestigious Eurostars Grant to Advance Their New Prototype Vaccine Against Streptococcus Suis Infection in Pigs CI
Intervacc AB Announces Changes in the Nomination Committee CI
Intervacc AB Announces Executive Changes CI
Intervacc Secures US Patent for Vaccine Against Infectious Disease Targeting Pigs MT
Intervacc AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Intervacc AB Announces Composition of Nomination Committee CI
Intervacc AB(OM:IVACC) dropped from S&P Global BMI Index CI
Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Intervacc President, CEO Resigns; Interim Successor Named MT
Intervacc AB Announces Executive Changes CI
Intervacc AB Announces Executive Changes CI
Intervacc AB Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova CI
Swedish Animals Vaccine Maker Intervacc Partners With Testa Center MT
Intervacc to Collaborate with Testa Center to Optimise Production Processes for Their Prototype Vaccine for Pigs CI
Intervacc AB Approves the Election of Boel Sundvall as Board Member CI
The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months CI
Veterinary Medicines Directorate Extends the Shelf Life for Intervacc AB's Strangvac, a Vaccine Against Equine Strangvac, to 33 Months CI
Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Intervacc Slumps 14% Amid Plan to Initiate SEK100 Million Rights Offering MT
Chart Intervacc AB
More charts
Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Company's candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Intervacc AB - Nasdaq Stockholm
  4. News Intervacc AB
  5. Intervacc Launches Horse Vaccine Strangvac in Britain